Taysha Gene Therapies (TSHA) Long-Term Debt Issuances (2020 - 2021)

Taysha Gene Therapies (TSHA) reported Long-Term Debt Issuances of $10.0 million for Q4 2021, up 36937.04% sequentially from $27000.0 in Q2 2020.

Taysha Gene Therapies (TSHA) Long-Term Debt Issuances (2020 - 2021) Analysis & Trends

Taysha Gene Therapies (TSHA) has 2 years of Long-Term Debt Issuances data on file, last reported at $10.0 million in Q4 2021.

For the quarter ending Q4 2021, Long-Term Debt Issuances changed N/A year-over-year to $10.0 million; the trailing twelve-month figure through Dec 2021 stood at $10.0 million (up 499.34% YoY), and the FY2021 full-year result was $10.0 million, up 497.73% from the prior year.
Long-Term Debt Issuances advanced to $10.0 million in Q4 2021, from $27000.0 in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $10.0 million in Q4 2021 to a low of $27000.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Taysha Gene Therapies	2.14 Bn	2.14 Bn	-	-

Download Data